Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 3.32B +182.3% |
| Revenue (ttm) | n/a |
| Net Income | -126.54M |
| EPS | -1.98 |
| Shares Out | 78.54M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 724,503 |
| Open | 41.78 |
| Previous Close | 42.76 |
| Day's Range | 40.91 - 42.76 |
| 52-Week Range | 10.91 - 45.76 |
| Beta | 3.12 |
| Analysts | Strong Buy |
| Price Target | 60.13 (+42.42%) |
| Earnings Date | May 7, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $60.13, which is an increase of 42.42% from the latest price.
News
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYV...
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and anti...
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin...
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second ...
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
“6 in '26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete a...
Spyre Therapeutics: Validated Targets, Optimized Delivery
Spyre Therapeutics offers a de-risked clinical pipeline and a robust cash runway extending into H2 2028, mitigating near-term financing risk. SYRE's portfolio targets validated mechanisms—alpha-4 beta...
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or tw...
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin...
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and r...
Intelligent Development Could Make Spyre Therapeutics Best In Show
Spyre Therapeutics has multiple potential best-in-class antibodies in its pipeline to treat ulcerative colitis, a trial design that tests combinations of these antibodies, and cash to run that trial. ...
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineeri...
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual do...
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerat...
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more th...
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
WALTHAM, Mass. , June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rati...
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
WALTHAM, Mass. , May 28, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, d...
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
On track for mid-year initiations of planned Phase 2 studies in ulcerative colitis ("UC") and rheumatoid arthritis ("RA"), providing for 7+ proof-of-concept readouts in 2026 & 2027 Reported extended f...
Spyre Therapeutics Announces Poster Presentations at Digestive Disease Week (DDW) 2025 Including Up to Eight months of Follow-up from an Ongoing Phase 1 Trial of SPY001
SPY001 is a novel, half-life extended α4β7 antibody in development for the treatment of Inflammatory Bowel Disease (IBD) SPY001 pharmacokinetic (PK) data up to eight months continues to support a pote...
Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody
Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience over first-generation anti-IL-...
Spyre Therapeutics: Targeting The Future Of IBD Treatment
Spyre Therapeutics is emerging as a key player in inflammatory bowel disease, with a focus on pathway-specific monoclonal antibodies for superior disease control. The company has a healthy balance she...